PLSH — Panacea Life Sciences Holdings Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Market Cap
$2.91m
Enterprise Value
$14.95m
Revenue
$2.38m

Annual cashflow statement for Panacea Life Sciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K/A	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-10.2	-10.9	-4.78	-9.14	-8.02
Depreciation
Amortisation
Non-Cash Items	5.28	7.96	-1.51	3.45	1.74
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-1.7	1.46	0.632	1.56	3.03
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-5.75	-0.7	-3.92	-2.4	-1.52
Capital Expenditures	-0.541	0	-0.163	-0.244	-0.065
Purchase of Fixed Assets
Other Investing Cash Flow Items	-1.5	0	0.685	0.047	0
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Cash from Investing Activities	-2.04	0	0.523	-0.197	-0.065
Financing Cash Flow Items	0.242	0.096	—	—	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	7.8	0.706	3.33	2.58	1.68
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	0.016	0.007	-0.065	-0.013	0.094